caa a22 4500 445312092 CHVBK 20180317142633.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s11095-011-0462-1 doi (NATIONALLICENCE)springer-10.1007/s11095-011-0462-1 Epithelial Profiling of Antibiotic Controlled Release Respiratory Formulations [Elektronische Daten] [Hui Ong, Daniela Traini, Mary Bebawy, Paul Young] ABSTRACT: Purpose: Release profiles of two ciprofloxacin hydrochloride formulations for the treatment of respiratory infection were evaluated using different in vitro methodologies and characterised for aerosol performance and toxicity. Methods: Spray-dried ciprofloxacin and ciprofloxacin spray-dried with polyvinyl alcohol as a controlled release (CR) agent at a 50:50 w/w ratio were formulated and physico-chemically characterised. Aerosol performances were assessed in vitro using a liquid impinger. Drug release was performed using a modified Franz cell and a validated air interface Calu-3-modified twin stage impinger (TSI). Ciprofloxacin toxicity was also established in vitro. Results: Both formulations had a similar size distribution, while CR ciprofloxacin had superior aerosol performance and stability. The release profiles showed the CR formulation to have a higher transport rate compared to ciprofloxacin alone in the cell model. Contrary results were observed using the diffusion cell. Results suggest that the air interface cell model provides a more physiologically relevant model than the modified Franz cell. Toxicity analysis showed that the lung epithelial cells could tolerate a wide range of ciprofloxacin concentrations. Conclusions: This study establishes that the in vitro modified TSI air interface Calu-3 model is capable of evaluating the fate of inhaled powder formulations. Springer Science+Business Media, LLC, 2011 Calu-3 air interface model nationallicence ciprofloxacin hydrochloride nationallicence controlled release nationallicence dry powder inhaler nationallicence polyvinyl alcohol nationallicence Ong Hui Advanced Drug Delivery Group, Faculty of Pharmacy (A15), The University of Sydney, 2006, Sydney, NSW, Australia aut Traini Daniela Advanced Drug Delivery Group, Faculty of Pharmacy (A15), The University of Sydney, 2006, Sydney, NSW, Australia aut Bebawy Mary Advanced Drug Delivery Group, Faculty of Pharmacy (A15), The University of Sydney, 2006, Sydney, NSW, Australia aut Young Paul Advanced Drug Delivery Group, Faculty of Pharmacy (A15), The University of Sydney, 2006, Sydney, NSW, Australia aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/9(2011-09-01), 2327-2338 0724-8741 28:9<2327 2011 28 11095 https://doi.org/10.1007/s11095-011-0462-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-011-0462-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ong Hui Advanced Drug Delivery Group, Faculty of Pharmacy (A15), The University of Sydney, 2006, Sydney, NSW, Australia aut NATIONALLICENCE 700 1- Traini Daniela Advanced Drug Delivery Group, Faculty of Pharmacy (A15), The University of Sydney, 2006, Sydney, NSW, Australia aut NATIONALLICENCE 700 1- Bebawy Mary Advanced Drug Delivery Group, Faculty of Pharmacy (A15), The University of Sydney, 2006, Sydney, NSW, Australia aut NATIONALLICENCE 700 1- Young Paul Advanced Drug Delivery Group, Faculty of Pharmacy (A15), The University of Sydney, 2006, Sydney, NSW, Australia aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/9(2011-09-01), 2327-2338 0724-8741 28:9<2327 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer